By Fineline Cube 
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. this week made another initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE), following its first attempt in November last year. ICBC International acts as the sole sponsor for the filing.
Company Overview and Pipeline
Since its inception in 2016, Hanx Bio has focused on developing next-generation immunotherapies, leveraging its expertise in structural biology, translational medicine, and clinical development. The company’s core product, HX009, is a bifunctional fusion protein targeting PD-1 and SIRPα. It is currently under clinical study in China for advanced melanoma, recurrent/refractory Epstein-Barr virus-positive non-Hodgkin’s lymphoma, advanced biliary tract cancer, and triple-negative breast cancer. HX009 has completed Phase I trials in Australia and China. Additionally, the company’s multi-target kinase inhibitor HX301 and anti-CTLA-4 antibody SIRPα fusion protein HX044 are both at clinical stages.-Fineline Info & Tech